A. Desai

发表

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

E. Small, S. Porten, E. Philip, 2021, Journal for ImmunoTherapy of Cancer.

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy

T. Walsh, M. King, S. Steinberg, 2019, Proceedings of the National Academy of Sciences.

Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer

A. Desai, V. Koshkin, T. Hope, 2020, Cancer medicine.

Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer

R. Bose, E. Small, J. Belkora, 2021, JCO oncology practice.

Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).

T. Seiwert, T. Karrison, A. Desai, 2018 .

Differential treatment outcomes in BRCA1/2‐, CDK12‐, and ATM‐mutated metastatic castration‐resistant prostate cancer

A. Wyatt, F. Feng, E. Small, 2021, Cancer.

Kidney Cancer, Version 3.2022

S. Hancock, R. Motzer, E. Jonasch, 2021 .

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options@@@Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

G. Dy, A. Desai, S. Menon, 2016 .

Progressive chronic lymphocytic leukemia after allogeneic hematopoietic cell transplantation.

A. Desai, P. McCarthy, M. Ross, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

Lauren L. Ritterhouse, D. Huo, Sabah Kadri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FGFR Signaling as a Target for Lung Cancer Therapy

A. Adjei, A. Desai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.

S. Hancock, R. Motzer, E. Jonasch, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer

N. Agarwal, Jason Zhu, O. Sartor, 2022, The oncologist.

Epithelial ovarian cancer: An overview.

C. Landen, W. Grizzle, Karan P. Singh, 2014, World journal of translational medicine.

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

G. Dy, A. Desai, S. Menon, 2016, Cancer biology & medicine.

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer

A. Sweet-Cordero, C. Onodera, E. Small, 2022, Frontiers in Oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

O. Sartor, P. Barata, A. Desai, 2020, Frontiers in Oncology.

Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.

E. Small, A. Desai, 2019, Future oncology.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

S. Hancock, R. Motzer, E. Jonasch, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis

T. Seiwert, T. Karrison, A. Desai, 2018, Journal of Thoracic Oncology.

Kidney cancer, version 1.2021: Featured updates to the nccn guidelines

S. Hancock, R. Motzer, E. Jonasch, 2020 .

Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor.

T. Demmy, G. Dy, A. Desai, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.

R. Bose, F. Feng, E. Small, 2021 .

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

R. Bose, E. Small, S. Porten, 2023, Frontiers in Oncology.

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.

Julian C. Hong, M. Meng, R. Bose, 2023, Clinical genitourinary cancer.

Change in neutrophil to lymphocyte ratio (NLR) as a predictor of treatment failure in renal cell carcinoma patients: Analysis of the IROC (Investigating RCC Outcomes) cohort.

P. Barata, A. Desai, V. Koshkin, 2021 .

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

Lauren L. Ritterhouse, D. Huo, Sabah Kadri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.

Julian C. Hong, R. Bose, F. Feng, 2022, Urologic oncology.

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

A. Desai, V. Koshkin, A. Basu, 2023, Cancer drug resistance.

Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.

A. Alva, A. Desai, V. Koshkin, 2021 .